New structure and operating model 'will prepare EMA for future challenges'
This article was originally published in Scrip
The European Medicines Agency has published details of its new organizational structure, which it says will allow it to focus on its key tasks and support its role in the EU drug regulatory system. Among the key changes are four new core divisions, improved co-ordination with stakeholders, and the addition of two major advisory functions on policy and program design.
You may also be interested in...
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.